[14C]-PC14586 for Healthy Volunteers

"The age limit for this clinical trial is 55 years old. All patients that wish to participate must be over the age of 18."

"The primary outcome of this study is to characterize the maximum plasma concentration of PC14586 and its metabolite M1 (PC16163) over the course of approximately one month. Secondary outcomes include identifying abnormal pulse rates after a single dose of PC14586, incidence of laboratory abnormalities based on hematology, clinical chemistry and urine test results, and finally, identification of adverse events after administration of PC14586."

"This specific trial, as noted on clinicaltrials.gov, is not currently looking for patients to enroll. The study was first posted on September 6th, 2020 and updated November 15th, 2020. Although this particular trial isn't seeking participants, there are 3 other trials that are actively recruiting right now."

"This trial is looking for 8 male volunteers between the ages of 18 and 55 who are in good health. Participants must also meet the following criteria: Creatinine clearance ≥90 mL/min determined using the Cockcroft-Gault equation., Healthy, non-smoking males of any race, between 18 and 55 years of age, with BMI between 18.0 and 32.0 kg/m2 inclusive., In good health, determined by no clinically significant findings from medical history and evaluations at screening and check-in as assessed by the investigator., Agree to use a highly effective method of contraception from check-in through 90 days"

"Given that [14C]-PC14586 is in Phase 1 of clinical trials, meaning there is limited safety and efficacy data currently available, our team at Power has given it a score of 1."